분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-03-31 12:41:38 , Hit : 976
 Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV


PBR Staff Writer
Published 27 March 2015
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Gilead Sciences' Sovaldi (sofosbuvir) for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis.


Sovaldi, a once-daily nucleotide analog polymerase inhibitor, is indicated for use in combination with ribavirin (RBV) for 12 weeks and the combination is the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection.

The approval is based on data from a Phase III trial conducted in Japan (Study GS-US-334-0118) among treatment-naïve and treatment-experienced genotype 2 patients.

In the trial, 96% of genotype 2 HCV-infected patients received 12 weeks of an all-oral regimen of Sovaldi plus RBV 600-1,000mg/day achieving a sustained virologic response 12 weeks after completing therapy (SVR12).

Gilead Research and Development executive vice-president and chief scientific officer Norbert Bischofberger said: "There is a need in Japan for new HCV treatment options that are more effective and better tolerated and we have been pleased to partner with the medical community here in Japan to demonstrate the efficacy and safety of Sovaldi.

"We look forward to making Sovaldi available in Japan as quickly as possible, while simultaneously continuing to work with the agency on its review of our second application for an all-oral sofosbuvir-based regimen for the treatment of genotype 1 HCV infection."

The Japanese approval is also supported by SVR12 results from four international Phase III trials FISSION, FUSION, POSITRON and VALENCE, which included genotype 2 HCV patients.

The company said that patients who achieve SVR12 are considered cured of HCV infection.

In September 2014, the company filed a new drug application (NDA) in Japan for a single-tablet regimen of sofosbuvir and the NS5A inhibitor ledipasvir to treat genotype 1 HCV infected patients.








867   중국의 인간배아 유전자편집 연구를 바라보는 상반된 시각  이성욱 2015/04/28 1371
866   유전자 조작인간배아를 만들어낸 중국과학자들  이성욱 2015/04/27 1039
865   항체를 이용한 HIV치료법  이성욱 2015/04/15 983
864   CRISPR의 능력을 배가(倍加)시키는 미니 유전자  이성욱 2015/04/02 1152
863   여러 질환에 대한 치료제의 가능성을 보여준 신물질  이성욱 2015/03/31 999
862   안젤리나 졸리 이번엔 난소 절제, `졸리 효과` 부활하나?  이성욱 2015/03/31 1000
  Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV  이성욱 2015/03/31 976
860   수지상 세포의 항암 작용을 향상시키는 갑상선 호르몬  이성욱 2015/03/30 1216
859   화학적 태그로 미래의 마이크로 RNA 표시  이성욱 2015/03/30 1485
858   생명탄생의 수수께끼를 해결한 화학자들  이성욱 2015/03/18 972
857   흔한 헤르페스 약물, 헤르페스 감염과는 별도로 HIV-1 수준 낮춘다.  이성욱 2015/03/17 1586
856   인간배아 DNA편집을 둘러싼 논란  이성욱 2015/03/17 1025
855   상처 치유 관련 미스터리 이해  이성욱 2015/03/17 948
854   First U.S. biosimilar is not considered interchangeable  이성욱 2015/03/11 998
853   Drug flushes out hidden AIDS virus  이성욱 2015/03/07 1055
852   숙주 세포와는 별도로 그 활성을 조절하는 HIV  이성욱 2015/03/03 1186
851   세균이 위협을 기억하는데 도움을 주는 바이러스 절단 효소  이성욱 2015/02/25 1258
850   iPS세포 '미니 간' 대량생산장치 개발  이성욱 2015/02/23 1043
849   Paying for gene therapy: are annuities the next big thing?  이성욱 2015/02/22 1022
848   부모의 특징을 자식에게 전달하는 방식: 박테리아의 DNA  이성욱 2015/02/19 1111

[이전 10개] [1].. 21 [22][23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN